Uloric and Sucralfate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Uloric (febuxostat) and Sucralfate (sucralfate). Common drug interactions include hypercholesterolaemia among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Uloric and Sucralfate. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Uloric?

Uloric has active ingredients of febuxostat. It is often used in gout. eHealthMe is studying from 8,067 Uloric users. Check the latest studies of Uloric.

What is Sucralfate?

Sucralfate has active ingredients of sucralfate. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 17,548 Sucralfate users. Check the latest studies of Sucralfate.

On Jul, 27, 2026

48 people who take Uloric and Sucralfate together, and have interactions are studied.

Uloric and Sucralfate drug interactions.

What are the common drug interactions of Uloric and Sucralfate, by gender? *:

female:

Hypercholesterolaemia (high levels of cholesterol in the blood)
Hypoacusis (loss of hearing)
Infection
Intestinal obstruction
Lacrimation increased
Leukocytosis (increased white blood cells)
Malabsorption (a state arising from abnormality in absorption of food nutrients across the gastrointestinal (gi) tract)
Neck pain
Oedema peripheral (superficial swelling)
Pelvi-ureteric obstruction (obstruction of the flow of urine from the renal pelvis to the proximal ureter)

male:

Chronic kidney disease
Renal failure (kidney dysfunction)
Nephrogenic anaemia (anaemia due to kidney disease)
Oedema peripheral (superficial swelling)
Renal injury (kidney injury)
Adverse drug reaction
Blood glucose decreased
Cheilitis (infection of lips)
Drug ineffective
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood)

What are the common drug interactions of Uloric and Sucralfate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Infusion site erythema (reddening of the skin at infusion site)
Infusion site rash
Infusion site urticaria (rash of round, red welts on the skin at infusion site)
Malaise (a feeling of general discomfort or uneasiness)
Neuropathy peripheral (surface nerve damage)
Renal tubular necrosis (death of kidney tubules)
Shock haemorrhagic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to excess bleeding)
Syncope (loss of consciousness with an inability to maintain postural tone)
Chronic kidney disease
Renal failure (kidney dysfunction)

60+:

Chronic kidney disease
Anaemia (lack of blood)
Muscle atrophy (a decrease in the mass of the muscle)
Nephrolithiasis (calculi in the kidneys)
Orthostatic hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up)
Pain
Pancreatitis (inflammation of pancreas)
Vitamin d deficiency
Pneumonia
Atelectasis (partial or complete collapse of the lung)

What are the existing conditions these people have? *

High Blood Pressure: 14 people, 29.17%
Pain: 11 people, 22.92%
Diabetes: 10 people, 20.83%
High Blood Cholesterol: 10 people, 20.83%
Infection: 8 people, 16.67%
Stress And Anxiety: 8 people, 16.67%
Headache (pain in head): 7 people, 14.58%
Depression: 6 people, 12.50%
Fluid Retention (an abnormal accumulation of fluid in the blood): 6 people, 12.50%
Neuropathy Peripheral (surface nerve damage): 6 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Uloric and Sucralfate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously